Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Would you offer RT to a patient who had a RP showing pT3b pN1 Gleason 9 prostate cancer with elevated post-op PSA?
Would it matter if their PET axumin was negative?
Answer from: Radiation Oncologist at Academic Institution
If Axumin PET is negative for metastatic sites (prostatic Bed or Pelvic Nodes are excluded) Or even totally negative, I would treat.
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
I would favor pet scan if meets threshold based on psa and plan treatment accordingly
Sign in or Register to read more
6190
6181
Related Questions
How do you interpret recent large retrospective analyses comparing radical prostatectomy vs. radiation for prostate cancer?
Why is there a benefit of ADT for high risk prostate cancer treated with radiation, yet no large trials describing benefit of adjuvant ADT after radical prostatectomy?
What time frame, number of PSAs, and calculator do you use for calculating PSA doubling times?
How do you manage a prostate cancer patient with pelvic lymphadenopathy and a single enlarged PSMA PET+ gastrohepatic node?
How do you manage significant gas in patients undergoing pelvic radiotherapy?
What is the rationale for the recent change in the NCCN criteria for very high risk prostate cancer?
How do you manage prostatic adenocarcinoma after a subtotal resection?
Would you add whole-pelvis radiation as MDT (metastasis-directed therapy) in a patient with 1 pelvic node and 2 osseous metastatic sites for castrate-resistant prostate cancer?
What are the realistic, modern 10-year survival curves for localized prostate cancer given the improvements we have made in diagnostics and treatment?
How do you incorporate absolute percent pattern 4 (APP4) into your risk stratification, specifically your recommendation for ADT for intermediate prostate cancer?